Antiphospholipid Antibodies and Infection:
COVID-19
antiphospholipid antibodies
antiphospholipid antibody syndrome
infection
thrombosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
03
2021
accepted:
28
05
2021
entrez:
5
7
2021
pubmed:
6
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
The clinical significance of antiphospholipid antibodies (aPL) in the context of infections has attracted attention since their first discovery in patients with syphilis. In fact, the recognition of aPL in patients with infections has been described in parallel to the understating of the syndrome. Since the first description of aPL-positive tests in three patients with COVID-19 diagnosed in January 2020 in Wuhan, China, a large number of studies took part in the ongoing debate on SARS-2-Cov 2 induced coagulopathy, and many following reports speculated a potential role for aPL. In order to get further insights on the effective role of detectable aPL in the pro-thrombotic status observed in COVID-19 patients, we performed an observational age-sex controlled study to compare the aPL profile of hospitalized patients with COVID with those observed in a) patients with thrombotic APS and b) patients with cultural/serologically-proved infections. Our data showed positive aPL testing in about half of the patients (53%) with COVID-19 and patients with other viral/bacterial infections (49%). However, aPL profile was different when comparing patients with overt APS and patients with aPL detected in the contest of infections. Caution is therefore required in the interpretation and generalization of the role of aPL s in the management of patients with COVID-19. Before introducing aPL testing as a part of the routine testing in patients with COVID-19, larger well-designed clinical studies are required. While the pro-thrombotic status in patients with COVID-19 is now unquestionable, different mechanisms other than aPL should be further investigated.
Identifiants
pubmed: 34220842
doi: 10.3389/fimmu.2021.687534
pmc: PMC8242935
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
687534Informations de copyright
Copyright © 2021 Sciascia, Radin, Bazzan, Montaruli, Cosseddu, Norbiato, Bertero, Carignola, Bacco, Gallo Cassarino and Roccatello.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Rheumatol. 2021 Jul;40(7):2939-2945
pubmed: 33464429
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):754-759
pubmed: 32723434
J Thromb Haemost. 2020 Jul;18(7):1569-1575
pubmed: 32619349
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Blood Coagul Fibrinolysis. 2021 Mar 1;32(2):73-79
pubmed: 33273262
Front Immunol. 2020 Oct 15;11:584241
pubmed: 33178218
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
J Invest Dermatol. 1960 Mar;34:219-22
pubmed: 14419136
Sci Transl Med. 2020 Nov 18;12(570):
pubmed: 33139519